Sona's 'THT' Cancer Therapy to be Assessed for Efficacy and Ability to Act as a Catalyst to Generate Immune Responses in Research Study

About this update from Sona Nanotech, Inc.

[{"type":"text","content":"Sona's 'THT' Cancer Therapy to be Assessed for Efficacy and Ability to Act as a Catalyst to Generate Immune Responses in Research StudyHalifax, Nova Scotia--(Newsfile Corp. - September 11, 2023) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the \"Company\" or \"Sona\") is pleased to announce an innovative research initiative to be undertaken with The Giacomantonio Immuno-Oncology Research Group (the \"Research Group\"). This study aims to evaluate the efficacy of Sona's Targeted Hyperthermia Therapy (\"THT\") technology in not only attenuating the development of colorectal, breast, and melanoma tumor models in mice but also in facilitating systemic immune responses. The study posits that the combined utilization of Sona's gold nanorods via its Targeted Hyperthermia Therapy, alongside precise immune modulation, will result in elevated immune activation and anti-tumor responses within the mouse models of colorectal cancer, breast cancer, and melanoma.Sona CEO, David Regan, commented, \"This innovative study will go significantly beyond our current plans for Targeted Hyperthermia Therapy applications to explore the potentially synergistic effect of its use with certain immunotherapy treatments for cancer. In it, we aim to harness the tremendous potential of immunotherapy, leveraging Sona's biocompatible gold nanorods as a pivotal, catalytic element. This effort marks the beginning of Sona delivering on the 'mountain of data' we committed to developing in support of our planned regulatory submissions for human clinical trial approvals.\"Dr. Carman Giacomantonio, principal investigator of the Research Group, commented, \"We are committed to exploring two distinct yet interrelated biological processes with the potential to unlock the elusive Holy Grail of intra-tumoral cancer immunotherapies, known as the Abscopal Effect. The first avenue capitalizes on the kinetic excitation of gold nanorods, capable of inducing localized tumor destruction. This process exposes potent tumor neo-antigens, which can then be strategically mobilized to immune-responsive sites. This strategy holds the potential of profoundly reshaping and amplifying the efficacy of the immune response against cancer. Concurrently, the second dimension of our research delves into the profound impact of intralesional immunomodulation in the context of both local and sys...

More updates from Sona Nanotech, Inc.